Remove 2024 Remove Drug Development Remove Pharmaceutical Manufacturing
article thumbnail

FOPE and PharmaState Academy complete second PULSE session on pharmaceutical quality systems

Express Pharma

The Federation of Pharma Entrepreneurs (FOPE) and PharmaState Academy announced the successful completion of the second session of the PULSE (Pharma Upgradation and Learning Series for Excellence) initiative, held on July 28, 2024. They also addressed data integrity, GDPR, and the need for change control in product manufacturing.

article thumbnail

Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

pharmaphorum

Located on the outskirts of the historic Italian city – home to Verdi and myriad architectural gems – the press launch and tour of the €85 million Chiesi development was a quintessentially Italian affair, based out of Chiesi’s San Leonardo production site. In-house drug development of biologicals and rare disease targeting.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma Analytics Quiz

PharmaState Academy

This quiz competition is brought to you by Pharma Industry Townhall – Sales & Marketing scheduled for 16th March 2024 at Radisson Blu, Marol, Andheri East, Mumbai. 2 / 15 In the Indian pharmaceutical industry, what does analytics-driven supply chain management primarily focus on?

article thumbnail

Q&A with Mrunal Jaywant: How the Discovery of Nitrosamines in Medicines Shifted the Pharmaceutical Manufacturing Landscape

Quality Matters

We have been monitoring the guidance published by different regulators with great interest -- here’s an overview of the latest updates, as of May 2024: U.S. We are focused on developing tools and resources that help companies navigate this issue and enhancing our knowledge of how regulators are enforcing current AI limits.

article thumbnail

CDMO acquires Meppel facility from Astellas

European Pharmaceutical Review

Delpharm has acquired the Meppel pharmaceutical manufacturing facility in the Netherlands from Astellas. The acquisition will strengthen the CDMO’s position in the Netherlands, where it already owns a manufacturing facility in Bladel and an injectable drug development centre in Leiden. billion in 2024.